Baseline characteristics of women screened with p16INK4a ELISA (n=1054)
| Characteristic | n* | Mean/median or n | SD (IQR) or per cent† |
|---|---|---|---|
| Age (mean, years) | 1054 | 34.5 | 7.8 |
| Relationship status | 1043 | ||
| Single | 76 | 7.3% | |
| Married | 565 | 54.1% | |
| Separated | 105 | 10.1% | |
| Widowed | 297 | 28.5% | |
| Number of current partners | 1053 | ||
| 0 | 269 | 25.6% | |
| 1 | 771 | 73.2% | |
| >1 | 13 | 1.2% | |
| Number of previous partners (median) | 1047 | 3 | (2–4) |
| Number of lifetime partners (median) | 1053 | 4 | (3–5) |
| Age of first intercourse (mean, years) | 1048 | 17.3 | 2.7 |
| Reproductive history | |||
| Gravidity (median) | 1054 | 3 | (2–4) |
| Parity (median) | 1053 | 3 | (1–4) |
| Currently experiencing vaginal symptoms‡ | 1050 | 397 | 37.8% |
| Amenorrhoea | 1050 | 165 | 15.7% |
| Postmenopausal§ | 1050 | 98 | 9.3% |
| Had vaginal delivery | 1042 | 953 | 91.5% |
| Had caesarean section | 1052 | 129 | 12.3% |
| History of STI | 1046 | 116 | 11.1% |
| Current contraceptive use | |||
| Any contraception | 1054 | 402 | 38.1% |
| Hormonal contraception | 1054 | 314 | 29.8% |
| Duration of contraceptive use (mean, moths) | 380 | 33.1 | 38.0 |
| Contraception by type | 402 | ||
| Oral contraceptives | 31 | 7.7% | |
| Injectable (Depo Provera) | 200 | 49.8% | |
| Implant (Jadelle or Norplant) | 83 | 20.6% | |
| Intrauterine device in situ (copper) | 10 | 2.5% | |
| Female sterilisation | 63 | 15.7% | |
| Condom only | 15 | 3.7% | |
| HIV-related characteristics | |||
| Time since first HIV diagnosis (mean, months) | 1054 | 45.1 | 29.7 |
| WHO stage | 1053 | ||
| 1 | 292 | 27.7% | |
| 2 | 310 | 29.5% | |
| 3 | 377 | 35.8% | |
| 4 | 74 | 7.0% | |
| Most recent CD4+ count (median, cells/dL) | 1054 | 506 | (355–685) |
| <200 | 91 | 8.6% | |
| 200–349 | 165 | 15.7% | |
| 350–499 | 255 | 24.2% | |
| ≥500 | 543 | 51.5% | |
| On HAART | 1054 | 824 | 78.2% |
| Time from HIV diagnosis to HAART initiation (mean, months) | 805 | 26.0 | 26.3 |
| Duration on current HAART (mean, months) | 1054 | 18.0 | 21.0 |
*N was different due to missing demographic information.
†Mean with SD was used to describe normally distributed variables. Median with IQR was used to describe non-normally distributed variables.
‡Vaginal symptoms included abnormal discharge, itching or pain with intercourse.
§Postmenopausal was not a subset of amenorrhoea.
HAART, highly active antiretroviral therapy; STI, sexually transmitted infection.